Shouyao holding (Beijing) Co., Ltd
Initial public offering and listing on the science and Innovation Board
Appendix to prospectus
1. Issuance recommendation 2. Financial report and audit report 3. Internal control assurance report 4. Non recurring profit and loss statement verified by certified public accountants 5. Legal opinion 6. Lawyer work report 7. Articles of Association (Draft) 8. Documents approved by the CSRC for the issuance and registration 9 Commitments made by the issuer and other responsible subjects related to the issuer's current issuance and listing
China Securities Co.Ltd(601066)
about
Initial public offering of shares by Shouyao Holdings (Beijing) Co., Ltd. and listing on the science and Innovation Board
Issuance recommendation
Sponsor
September, 2001
Securities issuance recommendation letter issued by the sponsor
Statement of recommendation institution and recommendation representative
China Securities Co.Ltd(601066) and the sponsor representatives of the project, Yang Huize and Li Yanzhi, are honest, trustworthy, diligent and conscientious in accordance with the company law of the people's Republic of China, the securities law of the people's Republic of China and other relevant laws and regulations, the relevant provisions of the CSRC and the relevant business rules of the Shanghai Stock Exchange The issuance recommendation letter is issued in accordance with the industry practice norms and ethical standards, and the authenticity, accuracy and completeness of the issuance recommendation letter are guaranteed.
Securities issuance recommendation letter issued by the sponsor
catalogue
interpretation...... Section 1 basic information of this securities issuance six
1、 The sponsor representative specifically responsible for the recommendation of this securities issuance six
2、 The sponsor of this securities issuance project and other members of the project team six
3、 Basic information of the issuer eight
4、 Explanation on whether the recommendation institution has any circumstances that may affect the fair performance of recommendation duties eight
5、 Internal audit procedures and core opinions of the recommendation institution nine
6、 The sponsor's verification of the filing of private investment funds Section 2 commitments of the sponsor 12 section III verification of relevant behaviors such as paid employment of third-party institutions and individuals thirteen
1、 Verification of the sponsor's paid employment of a third party and other related acts thirteen
2、 Verification of the issuer's paid employment of a third party and other related acts 13 Section IV recommendations for this offering fourteen
1、 The decision-making procedure of the Issuer on this issuance is legal fourteen
2、 This offering complies with relevant laws and regulations fifteen
3、 Issuer's main risk tips twenty
4、 Evaluation of the development prospect of the issuer thirty
5、 Recommendation conclusion of the recommendation institution on this securities issuance thirty-four
Securities issuance recommendation letter issued by the sponsor
interpretation
In this issuance recommendation letter, unless otherwise specified, the following words have the following specific meanings: 1. General terms
The issuer, the company and Shouyao holding (Beijing) Co., Ltd. are joint stock limited companies established by Shouyao company and Shouyao holding (Beijing) Co., Ltd. after overall change in August 2020
This public offering of 180000 A shares to the public
Sailintai refers to Beijing sailintai Pharmaceutical Technology Co., Ltd., which is a subsidiary of the company
Yizhuang SDIC refers to Beijing Yizhuang International Investment Development Co., Ltd., which is a shareholder of the company
Beijing Sl Pharmaceutical Co.Ltd(002038) refers to Beijing Sl Pharmaceutical Co.Ltd(002038) , a shareholder of the company
Shuanglu biology refers to Beijing Shuanglu Biotechnology Co., Ltd., a shareholder of the company and a Beijing Sl Pharmaceutical Co.Ltd(002038) wholly-owned subsidiary
Wangenxian refers to Beijing wangenxian Technology Development Center (limited partnership), which is the shareholder of the company
Chengzexin refers to Beijing chengzexin Technology Development Center (limited partnership), which is a shareholder of the company
Jiaxing Lingqi refers to Jiaxing Lingqi equity investment partnership (limited partnership), which is the shareholder of the company
Huagai Xincheng refers to Beijing Huagai Xincheng Yuanhang medical industry investment partnership (limited partnership), which is the shareholder of the company
Chongde Yingsheng refers to Beijing Chongde Yingsheng Venture Capital Co., Ltd., which is a shareholder of the company
Chongde Hongxin refers to Chongde Hongxin (Beijing) Investment Management Co., Ltd., which is the shareholder of Chongde Yingsheng investment management
Chunlin investment refers to Beijing Chunlin equity investment center (limited partnership), which is the shareholder of the company
The articles of association refers to the articles of association of Shouyao holding (Beijing) Co., Ltd
Articles of Association (draft refers to articles of association of Shouyao Holdings (Beijing) Co., Ltd.) China Securities Co.Ltd(601066) securities, sponsors, sponsors, lawyers of China Securities Co.Ltd(601066) lead underwriters and issuers, lawyers of Beijing Jingtian Gongcheng law firm, accountants of Jingtian Gongcheng issuer, Tianjian accountants Reporting committee refers to the auditor of Tianjian Certified Public Accountants (special general partnership)
Zhongshui Zhiyuan refers to Zhongshui Zhiyuan Assets Appraisal Co., Ltd
"Audit report" refers to the audit report with the document number of "(TJs [2021] No. 9568)" issued by the issuer's accountant
Securities issuance recommendation letter issued by the sponsor
"Three meetings" refers to the general meeting of shareholders, the board of directors and the board of supervisors of the company
The general meeting of shareholders refers to the general meeting of shareholders of Shouyao Holdings (Beijing) Co., Ltd
The board of directors refers to the board of directors of Shouyao Holdings (Beijing) Co., Ltd
The board of supervisors refers to the board of supervisors of Shouyao Holdings (Beijing) Co., Ltd
Company Law refers to the company law of the people's Republic of China
Securities Law refers to the securities law of the people's Republic of China
A share refers to the shares issued in China and approved to be listed on the stock exchange, with the face value indicated in RMB, subscribed and traded in RMB
The reporting period and the last three years refer to 2018, 2019, 2020 and January June 2021
Phase I
Shanghai stock exchange refers to Shanghai Stock Exchange
CDE refers to the drug evaluation center of the State Drug Administration
CSRC refers to the China Securities Regulatory Commission
Yuan, ten thousand yuan and one hundred million yuan refer to RMB yuan, ten thousand yuan and one hundred million yuan of the issuance recommendation letter, and the issuance recommendation letter China Securities Co.Ltd(601066) about the initial public offering of shares by Shouyao holding (Beijing) Co., Ltd. and its listing on the science and innovation board
2、 Technical terms
Sy-707 refers to ct-707 (conteltinib), a second-generation ALK inhibitor independently developed by xilintai, a wholly-owned subsidiary of the issuer
Sy-1530 refers to the BTK inhibitor independently developed by ct-1530, a wholly-owned subsidiary of the issuer
Sy-3505 refers to ct-3505, a third-generation ALK inhibitor independently developed by xilintai, a wholly-owned subsidiary of the issuer
ALK refers to anaplastic lymphoma kinase, a receptor tyrosine kinase. ALK gene mutation can lead to cancer
Wee1 refers to Wee1 protein kinase, which is a member of serine / threonine protein kinase family and an important protein regulating G2 / M cell cycle checkpoint
RET refers to RET receptor tyrosine kinase. RET gene can promote the occurrence and development of a variety of tumors by fusion mutation
Preparation refers to the drug that is made of API according to certain dosage form requirements to meet the needs of treatment or prevention, and can be finally provided to the medication object
Ind refers to the investigational new drug application, which refers to the application and approval process required for new drug research applications before starting human clinical trials
Inhibitors are drugs that can interact with target proteins and reduce their biological activity
Cro refers to contract research organization
Under laboratory conditions, preclinical research on the candidate drugs obtained in the compound research stage refers to the research activities of laboratory research and living animal research respectively, so as to observe the bioactivity of the compound to the target disease and evaluate its safety.
It mainly includes pharmacodynamics research, toxicology research and animal pharmacokinetics research. To apply for drug injection
Securities issuance recommendation letter issued by the sponsor
Preclinical research on drugs, including synthetic process, extraction method, physical and chemical properties and purity, dosage form selection, prescription screening, preparation process, test method, quality index, stability, pharmacology, toxicology, animal pharmacokinetics, etc. Traditional Chinese medicine preparation also includes the research on the source, processing and processing of original medicinal materials; Biological products also include the source, quality standard, preservation conditions, biological characteristics, genetic stability and immunological research of starting raw materials such as bacterial virus species, cell lines and biological tissues.
Systematic study of drugs in patients or healthy volunteers to reveal the safety of drugs in human body, the absorption, distribution, metabolism and excretion characteristics of test drugs and the therapeutic effect on diseases
The purpose of the preliminary clinical pharmacology and human safety evaluation test is to observe the human body's tolerance and pharmacokinetic characteristics of phase I clinical finger drugs, so as to provide basis for the subsequent phase II clinical formulation of drug administration plan. The subjects can be healthy volunteers
Phase II clinical trial refers to the preliminary evaluation of the therapeutic effect and safety of the trial drug on patients with target indications, and also provides a basis for the design of phase III clinical trial and the determination of dosage scheme
Phase III clinic further verified the therapeutic effect and safety of drugs on patients with target indications by expanding the number of subjects, evaluated the relationship between patient benefits and risks, and provided sufficient basis for drug registration application. Trials are generally randomized controlled trials with sufficient sample size
CRA refers to the clinical research association, that is, the clinical supervisor, who is responsible for the supervision of the formulation of relevant clinical trials
Conditional approval for listing refers to the drugs used to treat diseases that are seriously life-threatening and have no effective treatment means, rare diseases and drugs urgently needed in public health. The existing clinical research data have not met all the requirements of routine listing and registration, but the clinical conditional approval test of drugs has data to show the curative effect and predict its clinical value, Due to clinical urgent need, the listing is approved based on alternative endpoint, intermediate clinical endpoint or early clinical trial data when the quasi listing stipulates that the applicant must fulfill specific conditions. Conditional approval for listing does not include failure to meet the requirements of listing license due to defects in the design or implementation of clinical trials
Securities issuance recommendation letter issued by the sponsor
